The FTC challenged hundreds of pharmaceutical patent listings in an effort to encourage generics, including for blockbusters such as Ozempic and Victoza.

The FTC challenged hundreds of pharmaceutical patent listings in an effort to encourage generics, including for blockbusters such as Ozempic and Victoza.